Everest Medicines shareholder CBC Group expands holdings amid strategic expansion

CHINA—Everest Medicines has disclosed that its substantial shareholder, CBC Group, acquired 600,500 ordinary shares of the company on the open market in China between May 20 and 21, 2026.

The transaction totaled approximately HK$19.2 million (about US$2.46 million), reflecting an average purchase price of HK$31.91 (about US$4.08) per share.

This latest acquisition reinforces CBC Group’s position in the company and signals continued confidence in Everest Medicines’ long-term growth trajectory within the biopharmaceutical sector.

Sustained insider buying activity

Since December 2025, CBC Group, together with the company’s directors, has cumulatively purchased more than 3.062 million shares in the open market, amounting to over HK$113.8 million (US$14.56 million).

This steady accumulation highlights an ongoing commitment to increasing the company’s exposure amid evolving market conditions.

In parallel, Mr. Wei Fu, a non-executive director, honorary chairman of the Board, and substantial shareholder, also increased his holdings on two separate occasions in 2026.

On March 27, he acquired 860,000 shares valued at approximately HK$32.7 million (US$4.18 million), followed by a further purchase of 660,000 shares on May 14, valued at approximately HK$20.7 million (US$2.65 million).

These transactions collectively point to sustained insider confidence, while both CBC Group and senior leadership have indicated that additional share purchases remain possible, depending on regulatory compliance and market conditions.

Strategic global investment expansion

The heightened shareholding activity coincides with CBC Group’s announced merger agreement with GHO Capital, a leading European healthcare investment firm.

The deal is structured as a 50:50 merger of equals and is expected to close in early 2027.

Once completed, the combined platform is projected to manage more than US$21 billion in assets, creating one of the largest global healthcare-focused investment managers.

The expanded entity will operate across North America, Europe, and Asia-Pacific, regions that collectively account for around 90% of global healthcare research and development investment.

Growth momentum and pipeline expansion

Market observers note that the merger could enhance cross-regional capital allocation and strengthen Everest Medicines’ pathways for international expansion.

The company recorded 142% year-over-year revenue growth in 2025, driven largely by the strong performance of NEFECON®, which generated RMB 1.443 billion (US$200 million) in sales, representing over 300% growth.

Under its 2030 strategy, Everest Medicines aims to exceed RMB 15 billion (US$2.07 billion) in revenue, expand its commercial portfolio to more than 20 products, and accelerate its transition to a globally integrated biopharmaceutical platform.